心脏移植候选者中持久性左心室辅助装置使用率的虚假下降:移植注册登记中的选择偏倚
本研究比较OPTN STAR与SRTR机械循环支持文件在评估心脏移植候选者中持久性LVAD支持趋势和等待名单结局时的差异。SRTR队列LVAD患病率稳定(30.7%至37.4%),而STAR队列显示92.5%的下降(1740降至131例候选者),且STAR队列移植和死亡/恶化的3年累积发生率更高。结论认为STAR MCS文件排除当前列名候选者的LVAD,导致虚假下降和结局膨胀。
要点
- STAR MCS文件仅报告从等待名单移除的候选者设备,而SRTR MCS文件包括所有候选者设备。
- 使用STAR MCS文件分析LVAD支持会低估患病率并高估等待名单结局。
- 联合使用STAR的MCS和状态 justification文件可重复SRTR的估计结果。
核心结论
- STAR MCS文件排除当前列名候选者的LVAD,产生LVAD患病率和发生率的虚假下降以及膨胀的等待名单结局。
- 了解注册登记数据库的构建方式对于准确解读LVAD相关结局至关重要。
研究设计与样本
- 研究比较OPTN STAR和SRTR机械循环支持文件在评估心脏移植候选者中持久性LVAD支持趋势和等待名单结局的差异。
- 估计两个队列的移植和死亡/恶化累积发生率,并分析2018年10月至2025年4月每两月间隔的LVAD患病率。
主要发现
- SRTR队列显示LVAD患病率稳定(30.7%至37.4%)。
- 基于MCS文件的STAR队列显示LVAD患病率下降92.5%(1740降至131例候选者),尽管2025年4月30日有971例候选者以状态4列名接受LVAD支持。
- STAR队列LVAD植入后3年移植累积发生率更高(66.7% vs 54.4%),死亡/恶化累积发生率也更高(10.1% vs 4.5%)。
- 使用MCS和状态 justification文件重新运行基于STAR的分析,患病率和结局与SRTR估计一致。
临床怎么用
- 在解读LVAD相关结局时,应意识到注册登记数据库构建方式的影响,避免因使用STAR MCS文件而产生偏倚。
- 如需准确评估LVAD支持趋势和等待名单结局,建议联合使用STAR的MCS和状态 justification文件或使用SRTR MCS文件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Organ Procurement and Transplantation Network (OPTN) Standard Transplant Analysis and Research (STAR) files are commonly used to study use of mechanical circulatory support (MCS) among heart transplant candidates. However, the STAR MCS file reports devices only for candidates removed from the waitlist, whereas the Scientific Registry of Transplant Recipients (SRTR) MCS file includes devices for all candidates. We compared the STAR and SRTR MCS files in estimating trends in LVAD support and waitlist outcomes among heart transplant candidates with durable LVADs. METHODS: We identified adult heart transplant candidates who obtained durable LVADs between October 18, 2018 and December 31, 2024 using MCS files from STAR (N = 4182) and SRTR (N = 4919). We estimated the cumulative incidence of transplantation and death/deterioration in both cohorts and analyzed LVAD prevalence at bimonthly intervals from October 2018 to April 2025. RESULTS: The SRTR cohort showed stable LVAD prevalence (30.7% to 37.4%). In contrast, the STAR cohort constructed from the MCS file showed a 92.5% decline in LVAD prevalence (1740 to 131 candidates), despite 971 candidates listed with status 4 for LVAD support on April 30, 2025. The STAR cohort demonstrated higher 3-year cumulative incidence of transplantation (66.7% vs 54.4%) and death/deterioration (10.1% vs 4.5%) after LVAD implantation. When we reran STAR-based analyses with both MCS and status justification files, prevalence and outcomes matched SRTR estimates. CONCLUSIONS: The STAR MCS file excludes LVADs among currently listed candidates, producing artifactual declines in LVAD prevalence and incidence and inflated waitlist outcomes. Awareness of registry construction is essential for accurate interpretation of LVAD-related outcomes.
引用
- Ahn DJ, Lyden GR, Attia A, et al. Artifactual declines in durable LVAD utilization among heart transplant candidates: Selection bias in transplant registries. J Heart Lung Transplant. 2026. PMID: 42263896. doi:10.1016/j.healun.2026.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。